The Board of the company currently consists of one executive member and five non-executive members, each of whom is considered by the Board to be independent in character and judgment. The Board performs regular reviews of its composition as to background, function and experience, in order to ensure diversity and to balance knowledge of Idorsia’s business with fresh perspectives.
Board of Directors
Date of birth: 31 October, 1947
Nationality: French and American
Education: MSc in Pharmaceutical Science and PhD in Pharmacology from Louis Pasteur University, Strasbourg, France; MBA from Stanford University, CA, US.
Professional background: Various management positions at Schering-Plough. Within SmithKline Beecham, President of the pharmaceutical business in North America,1990; elected to the Board of Directors, 1992; Chairman, Pharmaceuticals, from 1994; Chief Operating Officer (COO), from 1995 and Chief Executive Officer (CEO), from 2000. First CEO of GlaxoSmithKline, 2001–2008. CEO of Laboratoires Pierre Fabre, 2008–2010.
Other activities and functions: Member of the Board of Directors of two listed companies, United Technologies Corporation, Radius Health, Inc., and one unlisted company, Alzheon, Inc. (Chairman). Operating Partner of the unlisted company Advent International Corporation. Member of the Advisory Board of Newman’s Own Foundation. Officer of the Legion of Honour and Knight Commander of the Order of the British Empire.
Date of birth: 19 December, 1961
Education: BA in Economics from Rutgers, the State University of New Jersey, US; Certified Public Accountant licensed in New York and New Jersey, US.
Professional background: Former Executive Vice President and Chief Financial Officer (CFO) of Schering-Plough Corporation; former President and CFO of Bausch & Lomb, Inc. Various executive positions at PricewaterhouseCoopers; former Member of the Board of Directors of Genzyme Corporation.
Other activities and functions: Member of the Board of Directors of two listed companies, Charles River Laboratories International, Inc., Bristol-Myers Squibb Company, and one unlisted company, Physicians World Speakers Bureau.
Date of birth: 3 April, 1955
Nationality: Swiss and French
Education: Medical degree in France; further training in pharmacology and physiology at the University of Montreal, Canada, and the University of California, San Francisco, US.
Professional background: Practicing cardiologist, 1980–1985. Head of Drug Discovery Group in the Cardiovascular Department of F. Hoffmann-La Roche, 1985–1997. Founder and CEO of Actelion, 1999–2017.
Other activities and functions: None.
Date of birth: 10 June, 1955
Education: Bachelor’s degree in Business Administration from Miami University, Oxford, Ohio, US; Master’s degree in Management (MBA equivalent) from Northwestern University, Illinois, US.
Professional background: CFO, 2004–2006, and President, International Operations, 2006–2009, at Baxter International, Inc.; President and CEO of Hill-Rom Holdings, Inc., 2010–2018.
Other activities and functions: Member of the Board of two listed companies, Hill-Rom Holdings, Inc., and Catalent, Inc., and Chairman of the Board of one unlisted company, Viant Corporation. Member of the Board of Ann and Robert Lurie Children’s Hospital.
Date of birth: 15 October, 1963
Education: MBA, Ecole Supérieure de Commerce de Paris.
Professional background: Held various executive positions such as Head of Finance and Control NBE at Nestlé, Group CFO of Galderma, Global Pharma Business unit CFO and EMEA CFO at Wyeth, Global Division CFO at Novartis OTC.
Other activities and functions: Member of the Board of Directors of one listed company, UCB, and two unlisted companies, Novo Holdings and NeoMedLight.
Date of birth: 6 May, 1956
Education: Université de Paris (Paris 7).
Professional background: Former Chairman of the Board of Cellartis AB; Executive Vice-President, Chief Operating Officer of Cellectis Group, CEO of Cellectis Therapeutics and CEO of ECTYCELL; Managing Director, Head of Global Pharma operations at Pierre Fabre SA: various management and EU regional management roles as well as senior corporate functions at WYETH Pharmaceuticals.
Other activities and functions: Independent director at the Board of VAXIMM AG, LNC SA, and member of the AFFIMED supervisory board, advisor at the EU Commission (Horizon 2020 Programme).
Elections and Terms of Office
Under Articles 13 and 16 of the Articles of Association, the 3–9 members of the Board of Directors are elected individually by the General Meeting of the Shareholders for a term of office corresponding to the legally permitted maximum term of one year. One year of office is understood to be the period from one ordinary Meeting of the Shareholders to the next ordinary Meeting of the Shareholders.
Time of First Election and Remaining Term of Office
|Date of AGM of first election||Date of AGM of end of term|
|Robert J. Bertolini||No||2017||2020|
|John J. Greisch||No||2017||2020|